ANTIBODY
Lupin partner Sandoz launches RanluspecTM across Europe for retinal disease treatment
Lupin Ltd has partnered with Sandoz to launch RanluspecTM, a biosimilar for Ranibizumab, across Europe. This launch will help to improve access to treatments for retinal and choroidal vascular diseases. The European Commission previously approved RanluspecTM in vial and syringe-filled presentations for medical use. The biosimilar targets conditions such as wet age-related macular degeneration and diabetic macular edema.
Why scientists call PJ.2.1 a ‘jump’ variant: The COVID strain that arrived with dozens of mutations at once and spreads by gripping your cells more tightly
A new variant of SARS-CoV-2, named PJ.2.1, was detected in Canada and has spread globally. It has over 25 mutations in its spike protein, which enhance its binding to human cells. Researchers are observing its spread in countries like the US, Spain, and Australia among others. Currently, there is no evidence linking PJ.2.1 to increased severity of illness or hospitalization.
Dario Amodei says AI could make cancer, Alzheimer’s ‘relics of the past’ in less than a decade as Anthropic expands AI-driven drug discovery push
Anthropic is collaborating with several pharmaceutical companies to utilize AI in drug development processes. These partnerships aim to improve the efficiency of drug discovery, addressing complex challenges in medical research. Notable projects include redesigning therapeutic molecules and accelerating antibody designs for various diseases. Anthropic has also initiated its own research on rare childhood muscular dystrophies, targeting potential clinical trials by late 2028.
More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger roles
India's family-run pharmaceutical companies are entering a new phase as the next generation takes on larger leadership roles and steers businesses towards complex generics, peptides, biologics, contract manufacturing and advanced therapeutics. Laurus Labs, Granules India, Bharat Biotech, Sun Pharma and Torrent Pharma are investing in capabilities that require greater scientific expertise, significant capital and longer gestation periods. The key question is whether the successors can turn these long-term bets into sustainable growth and create lasting value for investors.
Biocon CEO forecasts H2 results to outperform H1; company posts 52% fall in Q2 net profit; revenue up 2%
Biocon reported a 52% drop in second-quarter net profit due to shipment delays caused by geopolitical issues. The company expects revenue growth in the second half of fiscal 2027 from its biosimilars and insulin demand. Launches of pertuzumab in Europe and Brazil are anticipated soon, contributing to this growth. In the US market, their ustekinumab biosimilar has gained significant market share, boosting prospects.
Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini Piramal
In a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The company is actively diversifying its supply chains to provide greater flexibility against geopolitical challenges while broadening its manufacturing footprint to locations like India, the UK, and the US.
- Go To Page 1
AI halves drug discovery times, but =trial bottleneck remains a costly reality
Novo Nordisk, Sanofi and Dr Reddy’s Laboratories are among the companies exploring applications ranging from drug discovery to laboratory automation and research.
Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer
Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new indication allows treatment for adult patients with a combination of toripalimab, cisplatin, and paclitaxel. Approximately 80 percent of esophageal cancer cases in India are attributed to esophageal squamous cell carcinoma. The approval derives from positive results in the Phase 3 JUPITER-06 trial.
Bangladesh is battling measles. It's a 'real warning' to other nations
Bangladesh is currently handling the world's most significant measles outbreak, aggravated by declining vaccination rates. The World Health Organization reported over 200,000 suspected cases, with over 1,000 deaths primarily affecting children under five. Efforts to combat the outbreak have been hindered due to incomplete data and insufficient outreach. Many unvaccinated children are missing out on vaccinations, particularly in rural areas.
What is multiple myeloma? Louis Prevost, Pope Leo’s older brother, also battles cancer; his wife reveals shocking details
Louis Prevost, brother of Pope Leo XIV, is facing the challenges of multiple myeloma diagnosed back in 2017. Recent health issues have led him to participate in a hopeful clinical trial. Meanwhile, Pope Leo XIV is battling lung adenocarcinoma after undergoing surgery. Both brothers are united in their fight against these illnesses, with their family fostering a spirit of hope and receiving support from prayers.
These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analysts
Why should one be careful of the market at this juncture? One reason is that stocks are still not cheap. Even after all the nervousness of the past over two years, valuations have not come down to levels where you can say you are getting a bargain. When you buy something that is not cheap, you have less room for error, because the price already assumes things will go well.
Aragen Life Sciences begins operations at high-potency platform in Hyderabad
Aragen Life Sciences has initiated operations at its new high-potency manufacturing platform in Hyderabad. The facility, measuring 15,000 square feet, can produce 500-600 kg of active pharmaceutical ingredients annually. It aims to streamline the transition of highly potent molecules from discovery to commercial supply. The company has invested over Rs 1,000 crore in capital expenditures over three years.
Ukrainian aerospace engineer Anastasia Sevriukova preserved her eggs to have children after her life changed following stage 4 colon cancer diagnosis at 25
When Sevriukova was 25 she was diagnosed with stage 4 colon cancer while she was building her career as an aerospace engineer and had her future planned out with her fiance. She had to put both her career and her plans to start a family on hold as she has to go through the treatment.
‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO
Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadership in anti-obesity drugs through ongoing innovation and development. With successful trials for drugs like retatrutide and Foundayo, Lilly is expanding its product offerings. The company recognizes the importance of India as a growing market for healthcare investments and partnerships.
Charles Kelley diagnosed with rare blood cancer: Lady A singer plans to perform during treatment; What is Multiple Myeloma?
In a recent announcement, Charles Kelley from Lady A disclosed his battle with multiple myeloma, which was uncovered after suffering from unexplained rib fractures. He maintains a hopeful outlook regarding his treatment and has plans to keep performing. As Kelley gears up for a new Lady A album, he has also scheduled his first performances for December, emphasising the importance of family, music, and staying engaged through this challenging period.
Why is Summit Therapeutics share price up today by 22%?
Summit Therapeutics share price is up today by 22% after biopharma firm announced AstraZeneca would invest $2 billion in it. British drugmaker will collaborate on a series of studies testing their cancer treatments together.
Sun Pharma, Aurobindo Pharma, other stocks in focus as Trump exempts India from 100% tariffs on some speciality drugs
Indian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other countries from 100% tariffs on certain patented specialty pharmaceuticals and ingredients. Eligible products include rare-disease drugs, gene and cell therapies, and infertility treatments. Generic medicines remain outside the Section 232 tariffs.
US exempts India and 19 nations from 100% tariff on certain speciality drugs: Report
The United States has announced it will exempt certain speciality drugs and ingredients imported from India and 19 other countries from tariffs. This decision follows US President Donald Trump's proclamation imposing a 100% tariff on specified patented pharmaceuticals. Drugs intended for rare diseases and infertility, along with their components, will qualify for the zero-tariff treatment. The exemption applies to 20 other jurisdictions that have trade agreements with the US.
Bharat Biotech is 'back in action' after Covid reset: Krishna Ella on TB vaccine, Nipah-Ebola shots, gene therapy, IPO plans & what’s next
Bharat Biotech is “back in action” after a two-year post-Covid reset, founder Krishna Ella says, with the company expanding beyond vaccines into cell and gene therapy and monoclonal antibodies. The vaccine maker is advancing programmes for TB, Nipah, Ebola, chikungunya, malaria, Zika and antimicrobial resistance, while exploring an IPO to fund new therapies and potential acquisitions. Ella says the company, which currently has around Rs 2,000 crore in revenue and is debt-free, is focused on accelerating innovation and preparing the next generation to lead its human and veterinary businesses.
Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar Pebrilzo
Biocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, for HER2-positive breast cancer. The European Commission will take the final decision on marketing authorisation across the EU.
Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacity
Aragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-molecule CDMO capacity and a biologics facility. Aragen aims to transition from a molecules company to a medicines company through expansion. This strategic move aligns with global drugmakers seeking supply chain alternatives outside China. The firm is also developing its own intellectual property around antibody-drug conjugates.
Anthropic quietly sets up biology lab as it ramps AI drug program
At a time when fears of AI are gripping the public, the startup has built a wet lab, or place for physical experiments, in the San Francisco Bay Area, two people familiar with the matter said. Anthropic has said it wants to unlock treatments for rare diseases, and its biology work has gone beyond "in silico" or computer evaluations.
Scientists find DNA in human blood can fold into strange four-stranded shapes — a hidden layer of genetic information that ordinary sequencing may miss
Scientists have found unusual four-stranded DNA shapes in human blood plasma. These G-quadruplex structures suggest hidden genetic information may exist. Ordinary sequencing methods might miss this folded genetic material. This discovery could potentially offer new health clues in future research. Further studies will explore their exact role and origin within the body.
Agonisingly slow clinical trial is stopping Indian pharma become global innovator from supplier
India's regulatory hurdles slow down early-stage drug trials significantly. This complexity causes Indian companies to conduct crucial first-in-human studies abroad. Other nations like the US and Australia offer faster approval processes for trials. China now leads in novel medicine development due to its streamlined regulatory environment. Reforming India's system can unlock its potential in novel drug innovation.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the country’s PDP programme, providing access to around 70% of public-sector demand.
Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drug
In a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its collaboration with Bahiafarma and Bionovis. This partnership offers exclusive rights to supply the public healthcare sector in Brazil, with plans for phased localization of production. This endeavor aims to improve accessibility to critical cancer therapies while fostering local industry growth.
Why don't bats die from the lethal viruses they carry? A new DNA study uncovers a second genetic system hidden inside their blood not seen in mammals before
Researchers discovered vesper bats have two unique gene sets for antibody production. This unusual genetic arrangement has not been documented in any other mammal. This finding offers new insights into bat immunity and their disease tolerance. Scientists are now exploring how this system evolved and functions within bats. Understanding bat immunity could improve future disease outbreak research.
Load More
